NO20081133L - Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer - Google Patents
Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorerInfo
- Publication number
- NO20081133L NO20081133L NO20081133A NO20081133A NO20081133L NO 20081133 L NO20081133 L NO 20081133L NO 20081133 A NO20081133 A NO 20081133A NO 20081133 A NO20081133 A NO 20081133A NO 20081133 L NO20081133 L NO 20081133L
- Authority
- NO
- Norway
- Prior art keywords
- tieno
- carbonitriles
- pyridine
- protein kinase
- kinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72082105P | 2005-09-27 | 2005-09-27 | |
PCT/US2006/037502 WO2007038519A1 (en) | 2005-09-27 | 2006-09-27 | Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20081133L true NO20081133L (no) | 2008-04-25 |
Family
ID=37603099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20081133A NO20081133L (no) | 2005-09-27 | 2008-03-04 | Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070082880A1 (es) |
EP (1) | EP1937690A1 (es) |
JP (1) | JP2009511439A (es) |
KR (1) | KR20080059184A (es) |
CN (1) | CN101273047A (es) |
AR (1) | AR056200A1 (es) |
AU (1) | AU2006294726A1 (es) |
BR (1) | BRPI0616758A2 (es) |
CA (1) | CA2623228A1 (es) |
GT (1) | GT200600434A (es) |
NO (1) | NO20081133L (es) |
PE (1) | PE20070619A1 (es) |
RU (1) | RU2008108619A (es) |
TW (1) | TW200745137A (es) |
WO (1) | WO2007038519A1 (es) |
ZA (1) | ZA200802690B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276519B2 (en) * | 2002-11-25 | 2007-10-02 | Wyeth | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
TW200821318A (en) * | 2006-09-26 | 2008-05-16 | Wyeth Corp | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles |
US20090118276A1 (en) * | 2007-11-02 | 2009-05-07 | Wyeth | Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
US9029545B2 (en) | 2009-12-18 | 2015-05-12 | Glaxosmithkline Intellectual Property Limited | Thienopyridine NOX2 inhibitors |
WO2012030894A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
WO2012035421A2 (en) | 2010-09-17 | 2012-03-22 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
WO2012136120A1 (zh) * | 2011-04-02 | 2012-10-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 芳基丙烯酰胺化合物及其用于制备免疫抑制剂的用途 |
DK2838533T3 (da) | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
US9789116B2 (en) | 2013-10-15 | 2017-10-17 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
KR20240036709A (ko) * | 2016-03-11 | 2024-03-20 | 에이씨 이뮨 에스에이 | 진단 및 치료를 위한 바이사이클릭 화합물 |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
KR20210106506A (ko) | 2018-12-21 | 2021-08-30 | 셀진 코포레이션 | Ripk2의 티에노피리딘 억제제 |
CN114957280A (zh) * | 2021-12-31 | 2022-08-30 | 成都赜灵生物医药科技有限公司 | 噻吩[2,3-d]嘧啶衍生物及其用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196207A (en) * | 1977-05-23 | 1980-04-01 | Ici Australia Limited | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks |
EP1028964A1 (en) * | 1997-11-11 | 2000-08-23 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
US5948911A (en) * | 1998-11-20 | 1999-09-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives |
GB9906566D0 (en) * | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
BR0012157A (pt) * | 1999-07-07 | 2002-04-02 | Astrazeneca Uk Ltd | Derivado de quinazolina, derivado de pirimidina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para a prevenção ou tratamento de doenças ou condições médicas pela célula t um em animal de sangue quente em necessidade de tal tratamento |
JP2003525897A (ja) * | 2000-03-06 | 2003-09-02 | アストラゼネカ アクチボラグ | 治 療 |
EP1287001B1 (en) * | 2000-06-06 | 2004-09-29 | Pfizer Products Inc. | Thiophene derivatives useful as anticancer agents |
US20020004511A1 (en) * | 2000-06-28 | 2002-01-10 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
US6995171B2 (en) * | 2001-06-21 | 2006-02-07 | Agouron Pharmaceuticals, Inc. | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents |
WO2003103661A1 (en) * | 2002-06-06 | 2003-12-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES |
US7276519B2 (en) * | 2002-11-25 | 2007-10-02 | Wyeth | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
US7674907B2 (en) * | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
CN101056639A (zh) * | 2004-09-15 | 2007-10-17 | 詹森药业有限公司 | 噻唑并吡啶激酶抑制剂 |
BRPI0610322B8 (pt) * | 2005-05-20 | 2021-05-25 | Methylgene Inc | inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica |
-
2006
- 2006-09-25 AR ARP060104166A patent/AR056200A1/es unknown
- 2006-09-25 PE PE2006001155A patent/PE20070619A1/es not_active Application Discontinuation
- 2006-09-26 TW TW095135537A patent/TW200745137A/zh unknown
- 2006-09-27 AU AU2006294726A patent/AU2006294726A1/en not_active Abandoned
- 2006-09-27 KR KR1020087008455A patent/KR20080059184A/ko not_active Application Discontinuation
- 2006-09-27 CA CA002623228A patent/CA2623228A1/en not_active Abandoned
- 2006-09-27 CN CNA2006800357351A patent/CN101273047A/zh active Pending
- 2006-09-27 GT GT200600434A patent/GT200600434A/es unknown
- 2006-09-27 JP JP2008533522A patent/JP2009511439A/ja not_active Withdrawn
- 2006-09-27 RU RU2008108619/04A patent/RU2008108619A/ru not_active Application Discontinuation
- 2006-09-27 US US11/527,996 patent/US20070082880A1/en not_active Abandoned
- 2006-09-27 BR BRPI0616758-6A patent/BRPI0616758A2/pt not_active IP Right Cessation
- 2006-09-27 WO PCT/US2006/037502 patent/WO2007038519A1/en active Application Filing
- 2006-09-27 EP EP06804164A patent/EP1937690A1/en not_active Withdrawn
-
2008
- 2008-03-04 NO NO20081133A patent/NO20081133L/no not_active Application Discontinuation
- 2008-03-26 ZA ZA200802690A patent/ZA200802690B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2009511439A (ja) | 2009-03-19 |
RU2008108619A (ru) | 2009-11-10 |
US20070082880A1 (en) | 2007-04-12 |
AU2006294726A1 (en) | 2007-04-05 |
BRPI0616758A2 (pt) | 2011-06-28 |
CA2623228A1 (en) | 2007-04-05 |
TW200745137A (en) | 2007-12-16 |
CN101273047A (zh) | 2008-09-24 |
PE20070619A1 (es) | 2007-07-02 |
GT200600434A (es) | 2007-05-28 |
AR056200A1 (es) | 2007-09-26 |
EP1937690A1 (en) | 2008-07-02 |
ZA200802690B (en) | 2009-08-26 |
KR20080059184A (ko) | 2008-06-26 |
WO2007038519A1 (en) | 2007-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20081133L (no) | Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer | |
NO20045677L (no) | Inhibitorer av JAK- og CDK2-proteinkinaser | |
EA200801301A1 (ru) | ИНГИБИТОРЫ АКТИВНОСТИ Akt | |
NO20074666L (no) | Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer | |
GEP20084367B (en) | Diazepinoindole derivatives as kinase inhibitors | |
NO20055496L (no) | Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer | |
WO2007079164A3 (en) | Protein kinase inhibitors | |
NO20070731L (no) | Heterocykliske forbindelser. | |
NO20092668L (no) | 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl) -pyrimide derivatives useful as protein kinase inhibitors | |
NO20075987L (no) | Bisykliske derviater som p38-kinaseinhibitorer | |
WO2007044084A3 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
WO2004087699A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
WO2007023110A3 (en) | P38 map kinase inhibitors and methods for using the same | |
NO20076059L (no) | 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer | |
GEP20105054B (en) | Imidazoquinolines as lipid kinase inhibitors | |
NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
NO20081349L (no) | Pyrrolopyrimidinderivater som Syk-inhibitorer | |
NO20064000L (no) | Heteroarylkoblede pyrazoloderivater | |
NO20082476L (no) | Bicykliske forbindelser med kinaseinhiberende aktivitet | |
WO2007092095A3 (en) | [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases. | |
HK1093688A1 (en) | 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases | |
ATE493401T1 (de) | Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen | |
WO2006072612A3 (en) | Triazolophthalazines as pde2- inhibitors | |
DK1812440T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser | |
MY169791A (en) | Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |